Thank you for visiting the Janssen Oncology newsroom to learn more about our research that will be presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium
Janssen Oncology has 12 company-sponsored presentations at ASCO GU highlighting our robust solid tumor portfolio and pipeline, and the science we’re advancing for people with prostate cancer or bladder cancer.
You can learn more about what Janssen is doing to address the COVID-19 pandemic here.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, our vision is to eliminate cancer. We work tirelessly to advance science and innovation to address unmet medical needs and improve outcomes for patients. We aim to reimagine care, so people facing cancer can redefine living.
At the ASCO GU 2021 virtual meeting, Janssen will feature 12 presentations highlighting our latest research in prostate and bladder cancer. The data from these presentations underscore the clinical value of our portfolio and set the stage for future transformational therapies from our pipeline.
We are inspired by the progress that has been made in the treatment of genitourinary cancers and are pleased to be part of the important scientific exchange at ASCO GU with the goal of making a difference for patients. Thank you for visiting Janssen's ASCO GU 2021 Virtual Newsroom to learn more about our latest research.
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC.
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.